ETS-targeted therapy: can it substitute for MEK inhibitors?
The RAS/MAPK pathway has been intensively studied in cancer. Constitutive activation of ERK1 and ERK2 is frequently found in cancer cells from a variety of tissues. In clinical practice and clinical trials, sm...
Source: Clinical and Translational Medicine - Category: Internal Medicine Authors: Osamu Tetsu and Frank McCormick Source Type: research